ClinicalTrials.gg
CompletedNCT05553366Updated Aug 1, 2025Results posted

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

A Phase 3 interventional study of SUZ and HB/APAP in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 21 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,075
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing suzetrigine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. suzetrigine · Acute Pain.

Enrollment
2nd of 10
1,075 · median 165
Started
2022
with 1 other
Phase 3
2 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
6 of 10
Vertex Pharmaceuticals Incorporated

Among the 10 studies testing suzetrigine in Acute Pain, this one is the 2nd largest by enrollment, is one of 2 that started in 2022, is one of 2 in phase 3, and was the 3rd registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

3 of the 10 studies testing suzetrigine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing suzetrigine in Acute Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.

03

Conditions studied

  • Acute Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Before Surgery

    • Participants scheduled to undergo a primary unilateral bunionectomy with distal first metatarsal osteotomy (i.e., Austin procedure) and internal fixation under regional anesthesia (Mayo and popliteal sciatic block)
  • After Surgery

    • Participant is lucid and able to follow commands
    • All analgesic guidelines were followed during and after the bunionectomy

Key Exclusion Criteria:

  • Before Surgery

    • Prior history of bunionectomy or or other foot surgery on the index foot; or bunionectomy on the opposite foot
    • History of cardiac dysrhythmias within the last 2 years requiring anti-arrhythmia treatment(s)
    • Any prior surgery within 1 month before the first study drug dose
  • After Surgery

    • Participant had a type 3 deformity requiring a base wedge osteotomy, concomitant surgery such as hammertoe repair; or experienced medical complications during the bunionectomy
    • Participant had a medical complication during the bunionectomy that, in the opinion of the investigator, should preclude randomization

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,075 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to suzetrigine (SUZ) and hydrocodone bitartrate/acetaminophen (HB/APAP) for 2 days.

    Drug: Placebo (matched to SUZ) · Drug: Placebo (matched to HB/APAP)

  • Active comparator
    Hydrocodone bitartrate/acetaminophen (HB/APAP)

    Participants received HB 5 milligrams (mg)/ APAP 325 mg every 6 hours (q6h) for 2 days.

    Drug: HB/APAP · Drug: Placebo (matched to SUZ)

  • Experimental
    Suzetrigine (SUZ)

    Participants received SUZ \[100 mg as first dose, followed by 50 mg every 12 hours (q12h)\] for 2 days.

    Drug: SUZ · Drug: Placebo (matched to HB/APAP)

Interventions

  • DrugSUZ

    Tablets for oral administration.

    Also known as: VX-548

  • DrugHB/APAP

    Drug pages: Hydrocodone · Acetaminophen

    Capsules for oral administration.

  • DrugPlacebo (matched to SUZ)

    Placebo matched to SUZ for oral administration.

  • DrugPlacebo (matched to HB/APAP)

    Placebo matched to HB/APAP for oral administration.

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo

    SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated subtracting the baseline pain intensity score from the pain intensity score at each postdose time point (using pain rating score range: 0= no pain to 10= worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

    Time frame: 0 to 48 hours After First Dose of Study Drug

Secondary outcomes

  1. Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to HB/APAP

    SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each post dose time point(using pain rating score range: 0= no pain to 10= worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

    Time frame: 0 to 48 hours After First Dose of Study Drug

  2. Time to Greater Than or Equal to (≥)2-Point Reduction in NPRS,SUZ Compared to Placebo

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The time to ≥ 2-point reduction in NPRS from baseline was the time elapsed from the first dose of study drug until the first time the participant had at least a 2-point reduction in NPRS scores from baseline.

    Time frame: From Baseline Up to 48 Hours After First Dose of Study Drug

  3. Time to ≥1-Point Reduction in NPRS, SUZ Compared to Placebo

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The time to ≥1-point reduction in NPRS from baseline was the time elapsed from the first dose of study drug until the first time the participant had at least a 1-point reduction in NPRS from baseline.

    Time frame: From Baseline Up to 48 Hours After First Dose of Study Drug

  4. Percentage of Participants Reporting Good or Excellent on the Patient Global Assessment (PGA) Scale, SUZ Compared to Placebo

    The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 4-point Likert scale as: (poor, fair, good, or excellent). Percentage of participants who reported good or excellent on the PGA scale were reported.

    Time frame: At 48 Hours After First Dose of Study Drug

  5. Incidence of Vomiting or Nausea, SUZ Compared to HB/APAP

    The percentage of participants with the events of vomiting or nausea during the specified time frame was reported.

    Time frame: From Baseline up to Day 19

  6. Time-weighted SPID as Recorded on the NPRS From 0 to 24 Hours (SPID24), SUZ Compared to Placebo

    SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each post dose time point (using pain rating score range: 0= no pain to 10= worst possible pain). SPID24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).

    Time frame: 0 to 24 Hours After First Dose of Study Drug

  7. Time to First Use of Rescue Medication, SUZ Compared to Placebo

    Time to first use of rescue medication is the time from the first dose of study drug until the first use of rescue medication.

    Time frame: 0 to 48 Hours After First Dose of Study Drug

  8. Percentage of Participants Using Rescue Medication From 0 to 48 Hours, SUZ Compared to Placebo

    Time frame: 0 to 48 Hours After First Dose of Study Drug

  9. Total Rescue Medication Usage, SUZ Compared to Placebo

    Time frame: 0 to 48 Hours After First Dose of Study Drug

  10. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 19

07

Results

Posted Aug 1, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)
Started216431428
Safety set216431426
Completed208419418
Not completed81210
Withdrew: Withdrawal of consent (not due to ae485
Withdrew: Lost to follow-up333
Withdrew: Other non-compliance110
Withdrew: Randomized but not dosed002

Outcome measures

PrimaryTime-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo

SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated subtracting the baseline pain intensity score from the pain intensity score at each postdose time point (using pain rating score range: 0= no pain to 10= worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

Time frame:
0 to 48 hours After First Dose of Study Drug
Reported as:
Least squares mean · units on a scale
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo
units on a scalePlaceboSuzetrigine (SUZ)
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo70.6 ± 6.399.9 ± 4.5
Statistical analysis
  • Placebo vs Suzetrigine (SUZ) · ANCOVA · p = 0.0002
SecondaryTime-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to HB/APAP

SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each post dose time point(using pain rating score range: 0= no pain to 10= worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

Time frame:
0 to 48 hours After First Dose of Study Drug
Reported as:
Least squares mean · units on a scale
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to HB/APAP
units on a scaleHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to HB/APAP120.1 ± 4.599.9 ± 4.5
Statistical analysis
  • Hydrocodone Bitartrate/Acetaminophen (HB/APAP) vs Suzetrigine (SUZ) · ANCOVA · p = 0.0016
SecondaryTime to Greater Than or Equal to (≥)2-Point Reduction in NPRS,SUZ Compared to Placebo

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The time to ≥ 2-point reduction in NPRS from baseline was the time elapsed from the first dose of study drug until the first time the participant had at least a 2-point reduction in NPRS scores from baseline.

Time frame:
From Baseline Up to 48 Hours After First Dose of Study Drug
Reported as:
Median · minutes
Time to Greater Than or Equal to (≥)2-Point Reduction in NPRS,SUZ Compared to Placebo
minutesPlaceboSuzetrigine (SUZ)
Time to Greater Than or Equal to (≥)2-Point Reduction in NPRS,SUZ Compared to Placebo480 (476 to 716)240 (117 to 477)
Statistical analysis
  • Placebo vs Suzetrigine (SUZ) · Log Rank · p = 0.0016
SecondaryTime to ≥1-Point Reduction in NPRS, SUZ Compared to Placebo

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The time to ≥1-point reduction in NPRS from baseline was the time elapsed from the first dose of study drug until the first time the participant had at least a 1-point reduction in NPRS from baseline.

Time frame:
From Baseline Up to 48 Hours After First Dose of Study Drug
Reported as:
Median · minutes
Time to ≥1-Point Reduction in NPRS, SUZ Compared to Placebo
minutesPlaceboSuzetrigine (SUZ)
Time to ≥1-Point Reduction in NPRS, SUZ Compared to Placebo61 (34 to 121)60 (58 to 65)
Statistical analysis
  • Placebo vs Suzetrigine (SUZ) · Log Rank · p = 0.1315
SecondaryPercentage of Participants Reporting Good or Excellent on the Patient Global Assessment (PGA) Scale, SUZ Compared to Placebo

The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 4-point Likert scale as: (poor, fair, good, or excellent). Percentage of participants who reported good or excellent on the PGA scale were reported.

Time frame:
At 48 Hours After First Dose of Study Drug
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Good or Excellent on the Patient Global Assessment (PGA) Scale, SUZ Compared to Placebo
percentage of participantsPlaceboSuzetrigine (SUZ)
Percentage of Participants Reporting Good or Excellent on the Patient Global Assessment (PGA) Scale, SUZ Compared to Placebo53.261.7
Statistical analysis
  • Placebo vs Suzetrigine (SUZ) · Cochran-Mantel-Haenszel · p = 0.0343
SecondaryIncidence of Vomiting or Nausea, SUZ Compared to HB/APAP

The percentage of participants with the events of vomiting or nausea during the specified time frame was reported.

Time frame:
From Baseline up to Day 19
Reported as:
Number · percentage of participants
Incidence of Vomiting or Nausea, SUZ Compared to HB/APAP
percentage of participantsHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)
Incidence of Vomiting or Nausea, SUZ Compared to HB/APAP16.59.2
Statistical analysis
  • Hydrocodone Bitartrate/Acetaminophen (HB/APAP) vs Suzetrigine (SUZ) · Pearson's chi-squared test · p = 0.0014
SecondaryTime-weighted SPID as Recorded on the NPRS From 0 to 24 Hours (SPID24), SUZ Compared to Placebo

SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each post dose time point (using pain rating score range: 0= no pain to 10= worst possible pain). SPID24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).

Time frame:
0 to 24 Hours After First Dose of Study Drug
Reported as:
Least squares mean · units on a scale
Time-weighted SPID as Recorded on the NPRS From 0 to 24 Hours (SPID24), SUZ Compared to Placebo
units on a scalePlaceboSuzetrigine (SUZ)
Time-weighted SPID as Recorded on the NPRS From 0 to 24 Hours (SPID24), SUZ Compared to Placebo19.8 ± 3.030.6 ± 2.1
Statistical analysis
  • Placebo vs Suzetrigine (SUZ) · ANCOVA · p = 0.0032
SecondaryTime to First Use of Rescue Medication, SUZ Compared to Placebo

Time to first use of rescue medication is the time from the first dose of study drug until the first use of rescue medication.

Time frame:
0 to 48 Hours After First Dose of Study Drug
Reported as:
Median · minutes
Time to First Use of Rescue Medication, SUZ Compared to Placebo
minutesPlaceboSuzetrigine (SUZ)
Time to First Use of Rescue Medication, SUZ Compared to Placebo185 (143 to 210)157 (145 to 192)
Statistical analysis
  • Placebo vs Suzetrigine (SUZ) · Log Rank · p = 0.8592
SecondaryPercentage of Participants Using Rescue Medication From 0 to 48 Hours, SUZ Compared to Placebo
Time frame:
0 to 48 Hours After First Dose of Study Drug
Reported as:
Number · percentage of participants
Percentage of Participants Using Rescue Medication From 0 to 48 Hours, SUZ Compared to Placebo
percentage of participantsPlaceboSuzetrigine (SUZ)
Percentage of Participants Using Rescue Medication From 0 to 48 Hours, SUZ Compared to Placebo85.685.4
Statistical analysis
  • Placebo vs Suzetrigine (SUZ) · Cochran-Mantel-Haenszel · p = 0.9143
SecondaryTotal Rescue Medication Usage, SUZ Compared to Placebo
Time frame:
0 to 48 Hours After First Dose of Study Drug
Reported as:
Median · milligram
Total Rescue Medication Usage, SUZ Compared to Placebo
milligramPlaceboSuzetrigine (SUZ)
Total Rescue Medication Usage, SUZ Compared to Placebo800 (0 to 3200)800 (0 to 3200)
Statistical analysis
  • Placebo vs Suzetrigine (SUZ) · Wilcoxon rank-sum · p = 0.0205
SecondarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Day 19
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)
Participants with TEAEs76180132
Participants with SAEs000

Adverse events

Collected over Day 1 up to Day 19. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/216 (0%)0/216 (0%)51/216 (23.6%)
Hydrocodone Bitartrate/Acetaminophen (HB/APAP)0/431 (0%)0/431 (0%)113/431 (26.2%)
Suzetrigine (SUZ)0/426 (0%)0/426 (0%)72/426 (16.9%)
Most frequent other events
Most frequent other events
EventPlaceboHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)
NauseaGastrointestinal disorders23/21662/43135/426
HeadacheNervous system disorders20/21645/43121/426
DizzinessNervous system disorders11/21623/43115/426
ConstipationGastrointestinal disorders9/21622/43115/426

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)Total
Mean48.1 ± 13.548.3 ± 12.647.7 ± 13.348.0 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)Total
Female187359366912
Male297260161
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)Total
Hispanic or Latino84149131364
Not Hispanic or Latino132282295709
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboHydrocodone Bitartrate/Acetaminophen (HB/APAP)Suzetrigine (SUZ)Total
White160314285759
Black or African American4896116260
Asian87924
American Indian or Alaska Native07411
Native Hawaiian or other Pacific Islander0112
Other0235
Multiracial0369
Missing0123
08

Study locations

21 sites
  • Shoals Medical Trials Inc.
    Sheffield, Alabama 35660, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Trovare Clinical Research
    Bakersfield, California 93301, United States
  • Pacific Research Network Inc
    San Diego, California 92103, United States
  • New Hope Research Development
    Tarzana, California 91356, United States
  • New Hope Research Development
    West Covina, California 91790, United States
  • Clinical Pharmacology of Miami
    Hialeah, Florida 33014, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Kansas Spine and Specialty Hospital
    Wichita, Kansas 67226, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Center for Orthopaedic Reconstruction and Excellence
    Jenks, Oklahoma 74037, United States
  • HD Research LLC | First Surgical Hospital
    Bellaire, Texas 77401, United States
  • HD Research LLC | Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • HD Research LLC | Houston Heights Hospital
    Houston, Texas 77008, United States
  • Futuro Clinical Trials
    McAllen, Texas 78501, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • Houston Physicians Hospital
    Webster, Texas 77598, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Dec 2023, 14 months.

Results were first posted in Aug 2025, 1 year 7 months after primary completion. A results delay was requested in Dec 2024.

Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 14 months is above that.

Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2022
First posted
Sep 23, 2022
StartActual
Oct 3, 2022
Primary completionActual
Dec 15, 2023
CompletionActual
Dec 15, 2023
Results delay requested
Dec 13, 2024
Results first posted
Aug 1, 2025
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05553366
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Oct 3, 2022
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023
Results posted
Aug 1, 2025
Last update
Aug 1, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion